The macrophage migration inhibitory factor/CD74 axis in traumatic spinal cord injury: lessons learned from animal and human studies

Serina Rubio,Veerle Somers,Judith Fraussen
DOI: https://doi.org/10.1002/eji.202451333
2024-11-05
European Journal of Immunology
Abstract:Both animal and human studies have indicated the importance of MIF and CD74 in traumatic SCI. This review discusses how the MIF/CD74 axis affects numerous cell types and recovery post‐SCI and proposes a new path for investigation focused on B cells. Traumatic spinal cord injury (SCI) is a severe condition leading to long‐term impairment of motor, sensory, and autonomic functions. Following the initial injury, a series of additional events is initiated further damaging the spinal cord. During this secondary injury phase, both an inflammatory and immune modulatory response are triggered that have damaging and anti‐inflammatory properties, respectively. The proinflammatory cytokine macrophage migration inhibitory factor (MIF) and its receptor CD74 have been extensively studied in traumatic SCI. MIF expression is increased in spinal cord tissue after experimental SCI, mainly in astrocytes and microglia, as well as in the plasma of SCI patients. Functionally, MIF and CD74 were shown to regulate astrocyte viability, proliferation and cholesterol metabolism, microglia migration, and neuronal viability. Moreover, inhibition of the MIF/CD74 axis improved the functional recovery of SCI animals. We provide a detailed overview of studies analyzing the role of MIF and CD74 in traumatic SCI. We describe results from animal studies, using rat and mouse models for SCI, and human studies. Furthermore, we propose a new path for investigation, focused on B cells, that might lead to a better understanding of how MIF and CD74 contribute to the secondary injury cascade following traumatic SCI.
immunology
What problem does this paper attempt to address?